skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

The European Medicines Agency’s pharmacovigilance committee has recommended the withdrawal of all modified-release paracetamol products from the EU market as it could not find a way to adapt the management of paracetamol overdose to treat cases involving modified-release preparations.

 

 

OVERDOSE WITH MODIFIED-RELEASE PARACETAMOL IS DIFFICULT TO MANAGE

 

 

 

The European Medicines Agency’s pharmacovigilance committee PRAC has recommended the suspension of modified- or prolonged-release paracetamol products in view of the risks patients face from the complex way these medicines release paracetamol into the body after an overdose.

 

 

Modified-release paracetamol products, including those in combination with the opioid painkiller tramadol, are available in some EU member states under various brand names. As all these medicines are authorized by national procedures, the PRAC recommendations will now be sent to the EU Coordination Group for Mutual Recognition and Decentralised Procedures - Human (CMDh) for further action.

 

 

The PRAC recommended the removal of modified-release paracetamol products products from the market after it initiated a review in June last year at the request of Sweden’s Medical Products Agency, which had noted problems in managing overdose with these medicines.

 

 

The review showed that during an overdose, particularly at high doses, because of the way that paracetamol in modified-release products is released in the body, the usual treatment procedures for managing overdose developed for immediate-release products are not appropriate.

 

 

Th PRAC noted that in many cases, it may not be known whether an overdose of paracetamol involves immediate-release or modified-release products, making it difficult to decide what type of management is needed. If doctors are not aware that a patient has taken modified-release paracetamol, they may not be able to appropriately decide on when and for how long to give an antidote, and an overdose might result in severe liver damage or death, the committee said. In cases of modified-release products that also contain the painkiller tramadol, this risk could be complicated further because of the additional effects of overdose with tramadol.

 

 

The PRAC recommended the suspension of these medicines as it could not identify means to minimize the risk to patients, or a feasible and standardized way to adapt the management of paracetamol overdose across the EU to allow for treatment of cases that involve modified-release preparations. The committee concluded that that the risk following overdose with these medicines outweighs the advantage of having a longer-acting preparation.

 

 

Modified-release paracetamol products are available in Belgium, Denmark, Finland, Luxembourg, Portugal, Romania, and Sweden under various names, including Alvedon 665mg, Panadol Artro, Panadol Extend, Panadol Retard 8 hours, Panodil 665 mg, Paratabs Retard and Pinex Retard.

 

 

The PRAC review also covered modified-release medicines containing paracetamol with the opioid painkiller tramadol, which are available under the names Diliban Retard or Doreta SR in Bulgaria, Czech Republic, Estonia, Hungary, Iceland, Latvia, Lithuania, Poland, Portugal, Romania, Slovakia, Slovenia and Spain.

 

 

The PRAC’s recommendation does not apply to immediate-release paracetamol products.

お問い合わせ&レポートストア

専任スタッフによるデモンストレーションを兼ねたサービスの詳しいご説明、または無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。

*一部のサービスでは無料トライアルをご利用になれません。

ご質問等ございましたらお気軽にご連絡下さい。

日本(平日:9時~18時)
電話:+81 (0)3 6273 4260
Email:inquiry.jp@informa.com

オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。